YAGO NIETO to Neoplasm Recurrence, Local
This is a "connection" page, showing publications YAGO NIETO has written about Neoplasm Recurrence, Local.
Connection Strength
1.050
-
Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer. 2016 09 01; 122(17):2680-8.
Score: 0.150
-
Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors. Ann Oncol. 2015 Oct; 26(10):2125-32.
Score: 0.141
-
Prognostic analysis of pre-transplant peripheral T-cell levels in patients receiving an autologous hematopoietic progenitor-cell transplant. Bone Marrow Transplant. 2005 Sep; 36(5):425-30.
Score: 0.071
-
Ex Vivo Expanded Cord Blood Natural Killer Cells Combined with Rituximab and High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B Cell Non-Hodgkin Lymphoma. Transplant Cell Ther. 2024 Feb; 30(2):203.e1-203.e9.
Score: 0.063
-
High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. Transplant Cell Ther. 2023 Nov; 29(11):690-694.
Score: 0.062
-
Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. Haematologica. 2022 04 01; 107(4):899-908.
Score: 0.056
-
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. 2021 09; 35(9):2672-2683.
Score: 0.052
-
Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Transplant Cell Ther. 2021 05; 27(5):430.e1-430.e7.
Score: 0.052
-
Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysis. Br J Haematol. 2021 02; 192(3):560-567.
Score: 0.052
-
Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies. Br J Haematol. 2021 02; 192(4):e115-e120.
Score: 0.052
-
Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Leuk Lymphoma. 2018 04; 59(4):863-870.
Score: 0.041
-
Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Blood Adv. 2023 09 12; 7(17):4748-4759.
Score: 0.016
-
A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma. Blood. 2023 08 17; 142(7):621-628.
Score: 0.015
-
Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients. Blood Cancer J. 2023 05 03; 13(1):68.
Score: 0.015
-
NCCN Guidelines? Insights: Hematopoietic Cell Transplantation, Version 3.2022. J Natl Compr Canc Netw. 2023 02; 21(2):108-115.
Score: 0.015
-
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. Haematologica. 2023 01 01; 108(1):98-109.
Score: 0.015
-
Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation. Leuk Lymphoma. 2022 12; 63(12):2912-2917.
Score: 0.014
-
Post-Transplantation Cyclophosphamide Versus Tacrolimus and Methotrexate Graft-Versus-Host Disease Prophylaxis for HLA-Matched Donor Transplantation. Transplant Cell Ther. 2022 10; 28(10):695.e1-695.e10.
Score: 0.014
-
Mycophenolate Mofetil: A Friend or a Foe with Post-Transplantation Cyclophosphamide and Tacrolimus Prophylaxis in HLA-Matched Donors? Transplant Cell Ther. 2022 08; 28(8):500.e1-500.e10.
Score: 0.014
-
A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan???clofarabine in allogeneic stem cell transplantation. Bone Marrow Transplant. 2022 08; 57(8):1295-1303.
Score: 0.014
-
Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Transplant Cell Ther. 2023 04; 29(4):264.e1-264.e9.
Score: 0.014
-
Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma. Transplant Cell Ther. 2022 01; 28(1):32.e1-32.e10.
Score: 0.014
-
Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. JAMA Oncol. 2021 Jul 01; 7(7):993-1003.
Score: 0.013
-
Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy. Leuk Lymphoma. 2021 10; 62(10):2400-2407.
Score: 0.013
-
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Adv. 2021 03 23; 5(6):1648-1659.
Score: 0.013
-
Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. Biol Blood Marrow Transplant. 2020 08; 26(8):1439-1445.
Score: 0.012
-
Status of high-dose chemotherapy for breast cancer: a review. Biol Blood Marrow Transplant. 2000; 6(5):476-95.
Score: 0.012
-
Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. Leukemia. 2018 04; 32(4):986-995.
Score: 0.010
-
Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes. Clin Lymphoma Myeloma Leuk. 2018 01; 18(1):e41-e50.
Score: 0.010
-
The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation. Clin Lymphoma Myeloma Leuk. 2014 Feb; 14(1):e1-5.
Score: 0.008
-
High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. J Clin Oncol. 1998 May; 16(5):1661-8.
Score: 0.003
-
[High-dose chemotherapy with four drugs and peripheral blood progenitor cell autologous transplantation in disseminated breast cancer]. Med Clin (Barc). 1997 Dec 06; 109(20):775-81.
Score: 0.003